| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/20/2015 | US8937151 Gelatinase inhibitors and prodrugs |
| 01/20/2015 | US8937080 Pyrimidine substituted macrocyclic HCV inhibitors |
| 01/20/2015 | US8937074 Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances |
| 01/20/2015 | US8937048 Anti-angiogenic compounds |
| 01/20/2015 | US8937047 Biokinetics of fast-clearing polypeptides |
| 01/20/2015 | US8937046 Modulating the alternative complement pathway |
| 01/20/2015 | US8937045 Liquid formulations of tumor necrosis factor-binding proteins |
| 01/20/2015 | US8937044 Process for the synchronization of ovulation for timed breeding without heat detection |
| 01/20/2015 | US8937043 Method for obtaining a TGF-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/20/2015 | US8937042 Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
| 01/20/2015 | US8937041 Macrocyclic hepatitis C serine protease inhibitors |
| 01/20/2015 | US8937040 Antibiotic compositions for the treatment of gram negative infections |
| 01/20/2015 | US8937039 Peptide-based peroxidase inhibitors and methods of using same |
| 01/20/2015 | US8937038 Composition containing peptide ligand that bonds with CXCR2 for treating infective and inflammatory diseases |
| 01/20/2015 | US8936812 Tamper-resistant oral opioid agonist formulations |
| 01/20/2015 | US8936809 Method for treating prostate diseases based on local delivery of active substances |
| 01/20/2015 | US8936807 Use of the cathelicidin LL-37 and derivatives thereof for wound healing |
| 01/20/2015 | US8936806 Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration |
| 01/20/2015 | US8936804 Use of vanadium compounds to accelerate bone healing |
| 01/20/2015 | US8936792 Pseudomonas exotoxin a with reduced immunogenicity |
| 01/20/2015 | US8936790 Injection paradigm for administration of botulinum toxins |
| 01/20/2015 | US8936787 Peptides promoting lipid efflux |
| 01/20/2015 | US8936786 Methods and compositions for oral administration of protein and peptide therapeutic agents |
| 01/20/2015 | US8936784 Absorbable in situ gel-forming system, method of making and use thereof |
| 01/20/2015 | US8936782 Interferon beta as antibacterial agents |
| 01/20/2015 | US8936781 Macrocyclic compounds as hepatitis C virus inhibitors |
| 01/20/2015 | CA2789112C Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
| 01/20/2015 | CA2690399C Il-6 antagonist peptides |
| 01/20/2015 | CA2689798C Talaromyces emersonii beta-glucanases |
| 01/20/2015 | CA2633066C Enzymes for reduced immunological stress |
| 01/20/2015 | CA2593707C Fusion proteins comprising a non-cytotoxic protease, a targeting moiety, a protease cleavage site and a translocation domain |
| 01/20/2015 | CA2572915C Pharmaceutical composition containing botulinum neurotoxin |
| 01/20/2015 | CA2539575C Method of removing transition metals, especially from metathesis reaction products |
| 01/20/2015 | CA2498000C Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers |
| 01/20/2015 | CA2494132C Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes |
| 01/20/2015 | CA2464542C Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 01/20/2015 | CA2377204C Purification and stabilization of peptide and protein pharmaceutical agents |
| 01/15/2015 | WO2015006753A2 Therapies for diseases caused by arthropod-borne parasites |
| 01/15/2015 | WO2015006735A1 Nanoparticles and methods of producing the same |
| 01/15/2015 | WO2015006469A2 Method of treating fibroproliferative disorders including dupuytren ' s disease with one or more specific human matrix metalloproteinase and a tnf antagonist |
| 01/15/2015 | WO2015006419A1 Peptide inhibitors of calcium oxalate monohydrate crystallization and uses thereof |
| 01/15/2015 | WO2015006324A2 Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist |
| 01/15/2015 | WO2015006299A1 Pharmaceutical formulations of tranexamic acid and their use |
| 01/15/2015 | WO2015006228A1 Methods for treatment of and prophylaxis against inflammatory disorders |
| 01/15/2015 | WO2015006141A1 Carboxymethylcellulose-peptide conjugates and methods for using the same |
| 01/15/2015 | WO2015005787A1 Combination treatment for atopic dermatitis |
| 01/15/2015 | WO2015005748A1 Bioactive polypeptide monomer-immunoglobulin fc fragment conjugate having decreased receptor-mediated clearance, and method for preparing same |
| 01/15/2015 | WO2015005409A1 Aqueous ophthalmic composition containing cyclosporine a |
| 01/15/2015 | WO2015004604A1 Immunogenic tp0751 fragments |
| 01/15/2015 | WO2015004473A1 Compounds and methods for treatment or prevention of a pathogen infection |
| 01/15/2015 | WO2015004464A1 Suppression of itch |
| 01/15/2015 | WO2015004305A1 Peptide with quorum-sensing inhibitory activity, polynucleotide that encodes said peptide, and the uses thereof |
| 01/15/2015 | WO2015004255A1 Isolation of glycoproteins from brown algae |
| 01/15/2015 | WO2015004148A1 Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof |
| 01/15/2015 | WO2015004125A1 Pharmaceutical composition for a sustained release of lanreotide |
| 01/15/2015 | WO2015003623A1 Composition for treating osteoarthritis |
| 01/15/2015 | WO2015003581A1 Bivalent polypeptide inhibiting hiv infection |
| 01/15/2015 | WO2015003254A1 Therapeutic method of inducing mitochondrial biogenesis |
| 01/15/2015 | US20150020222 Neurotrophic factor manf and uses thereof |
| 01/15/2015 | US20150018747 Methods and compositions to treat myocardial conditions |
| 01/15/2015 | US20150018633 Unified Platform for Monitoring and Control of Blood Glucose Levels in Diabetic Patients |
| 01/15/2015 | US20150018535 Glycoprotein enriched composition as a food and/or feed additive and/or as a therapeutic agent |
| 01/15/2015 | US20150018526 Cytotoxins comprising modified bouganin toxin for the treatment of cancer |
| 01/15/2015 | US20150018486 Nanotherapeutic Colloidal Metal Compositions and Methods |
| 01/15/2015 | US20150018372 Delta opioid receptor agonist compounds |
| 01/15/2015 | US20150018287 Eye drops |
| 01/15/2015 | US20150018284 Formulations and methods of use for alpha connexin c-terminal (act) peptides |
| 01/15/2015 | US20150018281 Compositions and Methods for Uncoupling TrkB Receptor from PLC gamma 1 for the Treatment of Epilepsy and Anxiety-Like Disorder |
| 01/15/2015 | US20150018279 Compositions and methods for delivery of kinase inhibiting peptides |
| 01/15/2015 | US20150018277 Combination of a Leucine Source and an Omega-3 Unsaturated Fatty Acid Source for Use in the Treatment of Hypercalcaemia |
| 01/15/2015 | US20150018276 Method of treatment of cancer using guanosine 3', 5' cyclic monophosphate (cyclic gmp) |
| 01/15/2015 | US20150018275 Methods of improving behavioral therapies |
| 01/15/2015 | US20150018271 Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes |
| 01/15/2015 | US20150017727 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 01/15/2015 | US20150017699 Internally functionalized graphene substrates |
| 01/15/2015 | US20150017684 Streptococcus pyogenes antigens and corresponding dna fragments |
| 01/15/2015 | US20150017264 Procaspase 3 activation by combination therapy |
| 01/15/2015 | US20150017259 Integrin interaction inhibitors for the treatment of cancer |
| 01/15/2015 | US20150017255 Methods for treating cardiac conditions |
| 01/15/2015 | US20150017238 Methods and compositions for treating diabetes |
| 01/15/2015 | US20150017229 Method and system for synthesizing nanocarrier based long acting drug delivery system for insulin |
| 01/15/2015 | US20150017211 Delivery and formulation of engineered nucleic acids |
| 01/15/2015 | US20150017193 Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| 01/15/2015 | US20150017190 Use of epitopes inducing specific tolerance for the prevention of tissue rejection |
| 01/15/2015 | US20150017186 Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use |
| 01/15/2015 | US20150017181 Prevention of infection |
| 01/15/2015 | US20150017177 Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent |
| 01/15/2015 | US20150017175 Methods of administering anti-tnfalpha antibodies |
| 01/15/2015 | US20150017173 Antibodies to human transmembrane proteins |
| 01/15/2015 | US20150017164 COMBINATION OF BLyS AND/OR APRIL INHIBITION AND IMMUNOSUPPRESSANTS FOR TREATMENT OF AUTOIMMUNE DISEASE |
| 01/15/2015 | US20150017151 Pharmaceutical formulations of xanthine or xanthine derivatives, and their use |
| 01/15/2015 | US20150017150 Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract |
| 01/15/2015 | US20150017149 Pharmaceutical or nutritional compositions containing galactosidase, and their use |
| 01/15/2015 | US20150017148 Netrin loop peptide mimetics and uses thereof |
| 01/15/2015 | US20150017147 Methods and products to provide oral nutritional care to subjects with dementia |
| 01/15/2015 | US20150017146 Method of enhancing efficacy of blood transfusions |
| 01/15/2015 | US20150017134 Emt-inducing transcription factors cooperate with sox9 |
| 01/15/2015 | US20150017132 Mesenchymal Stem Cells and Uses Therefor |
| 01/15/2015 | US20150017130 Methods and compositions for inhibition of immune responses |
| 01/15/2015 | US20150017129 Preservation of the biological activity of undenatured type II collagen |